Ashina M, Dolezil D, Bonner JH, Zhou L, et al. A phase 2, randomized, double-blind, placebo-controlled trial of AMG 301, a pituitary adenylate cyclase-activating polypeptide PAC1 receptor monoclonal antibody for migraine prevention. Cephalalgia 2020 Nov 24:333102420970889. doi: 10.1177/0333102420970889.
PMID: 33231489